摘要
目的探讨达格列净联合二甲双胍对糖尿病合并冠心病患者氧化应激与糖脂代谢的影响。方法选择2019年3月至2020年3月于广东省化州市人民医院心血管内科治疗的2型糖尿病合并冠心病患者共50例,随机分为处理组和对照组,每组25例,其中处理组采用达格列净联合二甲双胍干预血糖,对照组采用二甲双胍干预,比较两组患者干预前和干预6个月后的氧化应激指标包括血清丙二醛(MDA)、超氧化物歧化酶(SOD)、总抗氧化能力(TAC),脂代谢指标包括低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)、甘油三酯(TG)和总胆固醇(TC);糖代谢指标包括糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后2 h血糖(2hPG)、空腹C肽。结果两组干预前的TAC、SOD、以及MDA水平对比差异无统计学意义(P>0.05),干预12周处理组的TAC和SOD水平均显著高于对照组,MDA水平显著低于对照组,差异具有统计学意义(P<0.05)。干预12周后处理组的TC、TG、LDL-C水平均显著低于对照组(P<0.05),处理组的HDL-C水平显著高于对照组(P<0.05),治疗12周后处理组FPG、2hPG和HbA1c水平显著低于对照组,而处理组的平均C肽水平显著高于对照组,差异具有统计学意义(P<0.05)。结论达格列净联合二甲双胍对糖尿病合并冠心病患者能显著提高机体抗氧化应激能力,改善患者的糖脂代谢。
Objective To investigate the effect of dapagliflozin combined with metformin on oxidative stress and glucose and lipid metabolism in patients with diabetes and coronary heart disease.Methods A total of 50 patients with type 2 diabetes and coronary heart disease who were treated in department of Cardiovascular Medicine of Huazhou People’s Hospital from March 2019 to March 2020 were selected and randomly divided into treatment group and control group,25 cases in each group,of which dapagliflozin was used in the treatment group Combined with metformin to interfere with blood glucose,the control group was treated with metformin.The two groups of patients were compared before the intervention and 6 months after the intervention for oxidative stress indicators(TAC,SOD,MDA),lipid metabolism indicators(TG,TC,LDL-C,HDL-C)and glucose metabolism indicators(HbAlc,FPG,2 hPG,fasting C peptide).Results There was no significant difference in the levels of TAC,SOD,and MDA between the two groups before intervention(P>0.05).The TAC and SOD levels of the 12-week intervention group were significantly higher than those of the control group,and the MDA level was significantly lower than the control group,The difference was statistically significant(P<0.05).After 12 weeks of intervention,the levels of TC,TG,LDL-C in the treatment group were significantly lower than those in the control group(P<0.05),and the HDL-C levels in the treatment group were significantly higher than those in the control group(P<0.05).After 12 weeks of treatment,the FPG and 2 h PG and Hb A1 c levels of the treatment group were significantly lower than those of the control group,while the average C peptide level of the treatment group was significantly higher than that of the control group,the difference was statistically significant(P<0.05).Conclusions Dapagliflozin combined with metformin can significantly improve the body’s ability to resist oxidative stress and improve the glucose and lipid metabolism of patients with diabetes and coronary heart disease.
作者
何航宇
廖伟亮
杨鸣宇
He Hangyu;Liao Weiliang;Yang Mingyu(Department of Cardiovascular Medicine,Huazhou People's Hospital,Guangdong Province,Huazhou 525100,China)
出处
《中华肥胖与代谢病电子杂志》
2021年第2期99-103,共5页
Chinese Journal Of Obesity and Metabolic Diseases：Electronic Edition
关键词
达格列净
二甲双胍
糖尿病
冠心病
氧化应激
Dapagliflozin
Metformin
Diabetes
Coronary heart disease
Oxidative stress
